Home > Insider Trading > Filing (0001181431-13-041153)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1302573	Oncomed Pharmaceuticals Inc	OMED	Pharmaceutical Preparations (2834)	383572512

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1270734	Deepika Pakianathan	Delphi Ventures 3000 Sand Hill Rd, Bldg 1, Ste 135 Menlo Park CA 94025		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2013-07-23	1,533,018	$0.00	1,533,018	No	4	C	Indirect	By Delphi Ventures VIII, L.P.
Common Stock	Acquisiton	2013-07-23	379,127	$17.00	1,912,145	No	4	P	Indirect	By Delphi Ventures VIII, L.P.
Common Stock	Acquisiton	2013-07-23	14,968	$0.00	14,968	No	4	C	Indirect	By Delphi BioInvestments VIII, L.P.
Common Stock	Acquisiton	2013-07-23	3,226	$17.00	18,194	No	4	P	Indirect	By Delphi BioInvestments VIII, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By Delphi Ventures VIII, L.P.
No	4	P	Indirect	By Delphi Ventures VIII, L.P.
No	4	C	Indirect	By Delphi BioInvestments VIII, L.P.
No	4	P	Indirect	By Delphi BioInvestments VIII, L.P.

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B-1 Preferred Stock	Disposition	2013-07-23	1,533,018	$0.00	1,533,018	$0.00
Common Stock	Series B-1 Preferred Stock	Disposition	2013-07-23	14,968	$0.00	14,968	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

Each share of Series B-1 Preferred Stock automatically converted on a one-to-one basis into Common Stock immediately prior to the consummation of the Issuer's initial public offering on July 23, 2013.
The Reporting Person is a managing member of Delphi Management Partners VIII, L.L.C ("DMP"), the general partner of each of Delphi Ventures VIII, L.P. and Delphi BioInvestments VIII, L.P. (collectively, the "Delphi Funds"). As a managing member of DMP, the Reporting Person shares voting and investment power over the shares held by the Delphi Funds and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such shares held by the Delphi Funds, except to the extent of her proportionate pecuniary interest therein.
The securities are immediately convertible.
The expiration date is not relevant to the conversion of these securities.